Rejection under alpha interferon therapy in liver transplant recipients

被引:44
作者
Walter, T.
Dumortier, J. [1 ]
Guillaud, O.
Hervieu, V.
Paliard, P.
Scoazec, J. -Y.
Boillot, O.
机构
[1] Federat Special Digest, Unite Transplantat Hepat, Lyon, France
[2] Hop Edouard Herriot, Serv Cent Anat Pathol, Lyon, France
关键词
HCV; interferon; liver transplantation; rejection; treatment;
D O I
10.1111/j.1600-6143.2006.01590.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Interferon alpha (IFN) is the corner stone drug for the treatment of recurrent hepatitis C (HCV) in liver transplant (LT) recipients. One of its serious potential adverse effects is acute and chronic rejection. The aim of this study was to review our experience using IFN-based therapy, in order to examine the incidence and the risk factors for rejection, and the outcome of patients who developed rejection. Between September 1990 and December 2004, 70 LT recipients were treated. Patients started antiviral treatment 16 (1-137) months after LT. Histological follow-up was available in all patients according to protocol biopsies. Rejection was diagnosed and graded according to Banff classification. Twenty-one percent of patients developed acute rejection (5 mild, 9 moderate and 1 severe) during IFN-based therapy. Patients were treated for 8 (1-15) months prior to rejection. Previous history of acute rejection before IFN therapy and treatment with pegylated-IFN was significantly associated with rejection (p = 0.04 and p = 0.02, respectively). The rejection was successfully treated in 87% of patients. No chronic rejection or graft losses were observed. Acute rejection under IFN-based therapy often occurs in LT recipients, but early diagnosis with protocol biopsies and early treatment can lead to a favorable outcome.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 43 条
[31]   INTERFERON-ALPHA-INDUCED ACUTE RENAL-ALLOGRAFT REJECTION [J].
MAGNONE, M ;
HOLLEY, JL ;
SHAPIRO, R ;
SCANTLEBURY, V ;
MCCAULEY, J ;
JORDAN, M ;
VIVAS, C ;
STARZL, T ;
JOHNSON, JP .
TRANSPLANTATION, 1995, 59 (07) :1068-1070
[32]   Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy [J].
Neff, GW ;
Montalbano, M ;
O'Brien, CB ;
Nishida, S ;
Safdar, K ;
Bejarano, PA ;
Khaled, AS ;
Ruiz, P ;
Slapak-Green, G ;
Lee, M ;
Nery, J ;
De Medina, M ;
Tzakis, A ;
Schiff, ER .
TRANSPLANTATION, 2004, 78 (09) :1303-1307
[33]  
Ning Q, 1998, J IMMUNOL, V160, P3487
[34]   High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation:: Relationship with rejection episodes [J].
Prieto, M ;
Berenguer, M ;
Rayón, JM ;
Córdoba, J ;
Argüello, L ;
Carrasco, D ;
García-Herola, A ;
Olaso, V ;
De Juan, M ;
Gobernado, M ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 1999, 29 (01) :250-256
[35]   Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin:: An open-label series [J].
Rodriguez-Luna, H ;
Khatib, A ;
Sharma, P ;
De Petris, G ;
Williams, JW ;
Ortiz, J ;
Hansen, K ;
Mulligan, D ;
Moss, A ;
Douglas, DD ;
Balan, V ;
Rakela, J ;
Vargas, HE .
TRANSPLANTATION, 2004, 77 (02) :190-194
[36]   Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C [J].
Ross, AS ;
Bhan, AK ;
Pascual, M ;
Thiim, M ;
Cosimi, AB ;
Chung, RT .
CLINICAL TRANSPLANTATION, 2004, 18 (02) :166-173
[37]   Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C [J].
Rostaing, L ;
Modesto, A ;
Baron, E ;
Cisterne, JM ;
Chabannier, MH ;
Durand, D .
NEPHRON, 1996, 74 (03) :512-516
[38]   Outcomes of acute rejection after interferon therapy in liver transplant recipients [J].
Saab, S ;
Kalmaz, D ;
Gajjar, NA ;
Hiatt, J ;
Durazo, F ;
Han, S ;
Farmer, DG ;
Ghobrial, RM ;
Yersiz, H ;
Goldstein, LI ;
Lassman, CR ;
Busuttil, RW .
LIVER TRANSPLANTATION, 2004, 10 (07) :859-867
[40]   Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation:: A randomized study [J].
Samuel, D ;
Bizollon, T ;
Feray, C ;
Roche, B ;
Ahmed, SNS ;
Lemonnier, C ;
Cohard, M ;
Reynes, M ;
Chevallier, M ;
Ducerf, C ;
Baulieux, J ;
Geffner, M ;
Albrecht, JK ;
Bismuth, H ;
Trepo, C .
GASTROENTEROLOGY, 2003, 124 (03) :642-650